The leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology”. It gives a robust idea about the patient recruitment status by geography, by Sponsor Company and by year for all the major orphan diseases in CNS and oncology. The report also compares the clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology. http://www.bharatbook.com/detail.asp?id=216686&rt=Clinical-Trial-Recruitment-in-Orphan-Diseases-Patient-Numbers-in-Ovarian-Cancer-Trials-Exceed-Other-Orphan-Diseases-in-Oncology.html
 
 Furthermore, the report provides profiles of prevalence forecast data up to 2017 for all the major indications. The major indications covered in the report are Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), ovarian disease, pancreatic disease, Hodgkin’s lymphoma, multiple myeloma and Acute Myeloid Leukemia (AML). It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. industry analysis reports
 
 An orphan disease is not common and its occurrence is said to be rare. These diseases have a low rate of prevalence in the existing population and a physician rarely gets to see patients with these conditions. Most of the orphan diseases are often genetic and hence they persist throughout a person’s life. It is estimated that 80% of orphan diseases have genetic origins. The remaining occurs due to allergies, degenerative causes, proliferative causes and as a result of infection. The symptoms for these diseases are not immediate and it occurs late for most of the conditions. The definition of orphan diseases varies with geography and is primarily dependent upon the prevalence of a disease.
 
 In the US, orphan diseases are those that affect fewer than 6.6 per 10,000 (Orphan drug Act 1983). The US National Organization for Rate Disorders (NORD) has more than 1,200 diseases in their list while National Institute of Health (NIH)’s office for rare diseases published a list of more than 6,000 disease disorders ranging from Aagenaes syndrome to Zuska’s Disease. In Europe, orphan diseases are those that have a prevalence of less than 5 per 10,000 of the population. According to European Organization for Rare Diseases (EURORDIS), there are about 6,000 to 8,000 orphan diseases that exist in Europe. In Japan, orphan diseases are those that have a prevalence of less then 4 per 10,000 (Orphan Drug Act 1993).
 
 The regulatory bodies play a crucial role in defining the orphan diseases as well as providing incentives to manufacturers who are involved in development of orphan drugs. Before the approval of orphan drugs, every molecule is designated as an orphan drug and will enter clinical trials. It is approved as an orphan drug only after the molecule clears the various phases in a clinical trial.
 
 Clinical trials are one of the most critical parts of the drug development process. The various aspects involved in clinical trials such as implementation of technology, efficient supply chain management, proper site selection, patient recruitment, database management and others are important. Clinical trial recruitment is a time consuming process therefore good strategies need to be followed by pharmaceutical companies for adequate patient recruitment.
 
 Scope
 
 - Insight on Clinical Trials conducted for major indications of cardiology such as Huntington’s disease, ALS, ovarian cancer, pancreatic cancer, Hodgkin’s lymphoma, multiple myeloma and AML from 2000 to 2010.
 - The status of patient recruitment by geography, Sponsor Company, year and stage of development.
 - The comparison of clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology
 - Analysis on the average number of patients recruited per trial for major indications per year.
 - Analysis on the average number of patients recruited per trial for major indications by stage of development.
 - The prevalence population in the US, Europe and Japan for all major indications from 2010-2017.
 
 Reasons to buy
 
 - Identify and understand the status of clinical trials conducted for major orphan diseases from 2000 to 2010.
 - Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.
 - Identify the prevalence within a population for major indications till 2017.
 - Identify the average number of patients recruited by stage of development and across years for all major indications and the comparison with other diseases.
 - Identify the indication in which the maximum number of trials is conducted and maximum number of patients recruited.
 
 For more information kindly visit :
 http://www.bharatbook.com/detail.asp?id=216686&rt=Clinical-Trial-Recruitment-in-Orphan-Diseases-Patient-Numbers-in-Ovarian-Cancer-Trials-Exceed-Other-Orphan-Diseases-in-Oncology.html
 
 Or
 
 Contact us at :
 
 Bharat Book Bureau
 Tel: +91 22 27578668 / +91 22 27579438
 Fax: +91 22 27579131
 Email: info@bharatbook.com
 Website: www.bharatbook.com
 Follow us on twitter: http://twitter.com/#!/Sandhya3B